iMDx to Release Fourth Quarter 2025 Results on March 26, 2026 and Attend Needham Virtual Healthcare Conference
Rhea-AI Summary
Insight Molecular Diagnostics (Nasdaq: IMDX) will report Q4 2025 financial results after market close on March 26, 2026, and will host a live Zoom webinar at 2:00 pm PT / 5:00 pm ET the same day with a Q&A session.
An archived replay will be available in the Investors/Events & Presentations section of the company website. Management will also attend the 25th Annual Needham Virtual Healthcare Conference and present in a virtual fireside chat on April 15, 2026.
Positive
- None.
Negative
- None.
News Market Reaction – IMDX
In the Mar 20 session, IMDX gained 8.67%, reflecting a notable positive market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 13 | Clinical performance data | Positive | +0.4% | Peer-reviewed study showed GraftAssure CM score outperforming other dd-cfDNA measures. |
| Mar 03 | Regulatory milestones | Positive | +10.3% | Completed key milestones advancing GraftAssureDx toward an FDA De Novo IVD submission. |
| Feb 11 | Equity financing | Negative | -22.7% | Announced $26.0M registered direct offering at $5.75 per share, indicating dilution. |
| Jan 13 | Industry endorsement | Positive | +1.7% | STAR working group paper supported decentralized, absolute dd-cfDNA testing aligned with GraftAssure. |
| Jan 07 | Investor conferences | Neutral | +0.0% | Announced participation in JPM Week and BTIG Snowbird investor conferences and meetings. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news reactions have consistently aligned with the underlying catalyst, with positive clinical and partnership updates seeing gains and financing news drawing a sharp selloff.
Over the past few months, IMDX has combined clinical progress with financing and commercial groundwork. In February 2026, a $26.0M registered direct offering triggered a -22.67% move, while a March milestone update on GraftAssureDx toward FDA De Novo submission coincided with a +10.32% reaction. Supportive transplant-monitoring commentary in January 2026 and positive GraftAssure data on March 13 both produced modest gains. The current earnings-date and conference announcement follows a pattern of active investor outreach alongside advancing transplant diagnostics.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NASHVILLE, Tenn., March 20, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced that it will report fourth quarter 2025 financial results after the market closes on Thursday, March 26, 2026. iMDx will host a live Zoom webinar to discuss the company's financial results at 2:00 pm PT / 5:00 pm ET that same day.
The live webinar to discuss financial results, followed by Q&A, will be accessible via registration at the following link: iMDx Q4 2025 Earnings Webinar.
An archived replay will be available after the call concludes on iMDx’s website within the Investors/Events & Presentations section here.
Attendance at 25th Annual Needham Virtual Healthcare Conference
Separately, on April 15th, Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James will attend the 25th Annual Needham Virtual Healthcare Conference, taking place from April 13-16, 2026.
Event: 25th Annual Needham Virtual Healthcare Conference
Presentation Date: April 15, 2026
Format: Virtual fireside chat
Webcast: Click here
iMDx management will also be conducting one-on-one meetings with investors at the conference. Investors wishing to book a meeting are encouraged to reach out to their Needham sales representative.
About Insight Molecular Diagnostics Inc.
Insight Molecular Diagnostics is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. Investors may visit https://investors.imdxinc.com/ for more information.
GraftAssureCore™, GraftAssureIQ™, GraftAssureDx™, VitaGraft™, GraftAssure™, DetermaIO™, and DetermaCNI™ are trademarks of Insight Molecular Diagnostics Inc.
Investor Contact:
Alexandra Grossman
LifeSci Advisors LLC
alex@lifesciadvisors.com
